Latest News

 Filter by Provider

Production ramp is underway, but converting commitments into revenue is the test.

Deferred revenue and AAA development shaped this quarter's growth story.

Divestitures reshaped the balance sheet, but R2 sales slipped on liquidity strain.

Interim leadership reaffirmed guidance as the board searches for a permanent CEO.

YCANTH sales hit a record while Gorlin syndrome becomes a new target.

You might think it'll save you money, but it could cost you.

Battery storage nears completion as leverage falls and EBITDA rises sharply.

Founder Daniel Cohen returns as CEO as AI and space bets take shape.

Fuel volumes climbed while LPG margins and river navigation weighed on results.

Walmart's stock has been surging -- and shares are now richly valued.

Labcorp (NYSE:LH) Chief Financial Officer Julia Wang said strength in the company’s central laboratory business and diagnostic testing helped drive third-quarter growth, while management prepares for a potential reduction in government reimbursement rates in 2027. Speaking at the UBS Global Healthc

Milestone Pharmaceuticals (NASDAQ:MIST) plans to cut operating expenses by approximately 30% as it seeks to extend its cash runway while building sales of CARDAMYST and advancing a late-stage clinical trial. The company reported approximately 1,800 CARDAMYST prescriptions in the third quarter of 20

SBC Medical Group (NASDAQ:SBC) reported fiscal third-quarter revenue of $59 million, up 35% from a year earlier, as higher management service fees, rental revenue and a newly consolidated business helped lift operating income by 66%. The medical services company reported operating income of $26 mil

Braskem (NYSE:BAK) reported a 63% sequential decline in third-quarter recurring EBITDA to $382 million, as petrochemical spreads retreated from elevated second-quarter levels across its reporting segments. Rosana Avolio, director of investor relations, strategic planning and global market intellige

ImmuCell (NASDAQ:ICCC) reported a 46% increase in third-quarter product sales and returned to profitability as improved manufacturing output and stronger demand supported its First Defense calf-health products. The company’s unaudited product sales rose to $8 million for the quarter ended Sept. 30,

Arrive AI (NASDAQ:ARAI) reported third-quarter revenue of $39,700, up from $7,450 a year earlier, as an expansion at Hancock Health helped drive sales of its automated delivery technology. The company said it is targeting 100 Arrive Point deployments in 2027 while managing costs and working to regai

Digi Power X (NASDAQ:DGXX) reported an 85% sequential increase in third-quarter revenue as its artificial intelligence business grew, while outlining construction and financing milestones for its Alabama data center. Revenue rose to $12.25 million, up 50% from a year earlier. AI revenue was $5.66 m

Accelevation (NASDAQ:ACCV) reported a 66% increase in third-quarter revenue and a record $1.7 billion backlog, as demand for data center infrastructure and modular products fueled orders in its first quarter as a public company. The company generated approximately $202 million in revenue, up more t

Credit provisions and carrier delays weighed on results, with a pipeline push ahead.

Lineage adds a Huntington's program and shifts its cash runway outlook.

Direct product sales are gaining traction as grant funding shrinks.

Dell Technologies has dropped significantly on the stock market lately, but its impressive growth can trigger a bull run in 2027.

With earnings season winding down and the AI-driven volatility finally abating, it's time to start making some assessments that will guide your decisions into and through the year ahead.

Jefferson Capital keeps its cost base flexible by outsourcing call centers, letting expenses scale with purchasing volume.

Revenue fell 20% as management reset assortments, cut costs and pursued lender talks.

Margins hit a five-year high as costs fell and a Tier 1 deal starts adding revenue.

Acquisitions lifted sales sharply, but margins slipped on rising commodity costs.

Credit losses rose and guidance was cut, testing the Brazilian payments firm.

Acquisitions and a new permanent capital vertical drove a standout quarter.

Is the AI cloud provider's "timing, not demand" explanation a good enough reason to buy the dip?

Medical seat growth and tuition gains met margin pressure and a pending merger.

Margins climbed to their strongest level since 2023 even as Latin American currency pressure builds.

Revenue rose 22% as debt was fully retired and new products advanced.

Operating costs climbed 18% as warehouse labor scaled, so margin gains depend on whether management can curb fulfillment expenses.

Political demand and digital gains partly offset steep ad declines this quarter.

The stock has averaged a 20% annual return over the past 60 years.

The iPhone maker now has a commanding market cap lead over the data center chipmaker.

Here are some considerations to be aware of if you plan on using a TFSA for an emergency fund.

Cerebras avoids the high-bandwidth memory shortage that squeezes rivals, so its chip costs depend less on memory prices.

Shifting to branded drugs and a leaner marketing budget reshapes its subscriber strategy.

Service business hits first positive gross margin after a major acquisition.

Record quarterly deployments came from auto finance and a new Mexico push.

Management details its ZENITH trial expansion and late-stage dermatology plans.

Losses narrowed sharply as the company bets on a major European acquisition for 2027.

History sends a clear message about where stocks may be headed.

Houston occupancy slipped while North Dallas absorption stays tough.